Screener
Capricor Therapeutics CAPR EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The source filing: Capricor Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 5:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-060382
| REVENUE / TOTAL REVENUE | Three Months Ended March 31, 2026 / — | Three Months Ended March 31, 2025 / — |
|---|---|---|
| LOSS BEFORE INCOME TAXES | (33,941,345) | (24,391,594) |
| (Provision for) benefit from income taxes | — | — |
| NET LOSS | $(33,941,345) | $(24,391,594) |
| OTHER COMPREHENSIVE INCOME (LOSS) | ||
| Net unrealized gain (loss) on marketable securities | (536,881) | 784,972 |
| COMPREHENSIVE LOSS | $(34,478,226) | $(23,606,622) |
| Net loss per share, basic and diluted | $(0.59) | $(0.53) |
| Weighted average number of shares, basic and diluted | 57,434,267 | 45,636,633 |
Item 1. Financial Statements.
FAQ
- What is Capricor Therapeutics's EPS (basic)?
- Capricor Therapeutics (CAPR) reported EPS (basic) of -$0.59 in Q1 2026.
- How has Capricor Therapeutics's EPS (basic) changed year-over-year?
- Capricor Therapeutics's EPS (basic) decreased by 11.3% year-over-year, from -$0.53 to -$0.59.
- What is the long-term trend for Capricor Therapeutics's EPS (basic)?
- Over 4 years (2021 to 2025), Capricor Therapeutics's EPS (basic) has grown at a 27.0% compound annual growth rate (CAGR), from -$0.87 to -$2.26.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.
Ask your AI about Capricor Therapeutics's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude